Filgrastim Production Cost Reports

The report provides a detailed analysis essential for establishing a Filgrastim production plant. It encompasses all critical aspects necessary for Filgrastim production, including the cost of Filgrastim production, Filgrastim plant cost, Filgrastim production costs, and the overall Filgrastim production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Filgrastim production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Filgrastim is a recombinant therapeutic protein that finds wide applications in the medical and pharmaceutical fields. It is primarily used to stimulate the production of white blood cells, especially neutrophils, in patients with weakened immune systems. Its main application is in cancer treatment, where it helps reduce the risk of infections in patients undergoing chemotherapy or radiation therapy. It is a recombinant human granulocyte colony-stimulating factor used to treat neutropenia and prevent febrile neutropenia in patients receiving myelosuppressive chemotherapy or radiation therapy. It is also used in patients receiving bone marrow or stem cell transplants to support faster recovery of immune function. In addition, it is prescribed for individuals with severe chronic neutropenia and is used in clinical settings to mobilise stem cells for collection prior to transplantation.

The market for filgrastim is predominantly driven by its demand as a recombinant granulocyte colony-stimulating factor medication in haematology and oncology for managing low white blood cell counts. Its application as a drug to boost neutrophil production in patients undergoing chemotherapy, radiation, or bone marrow transplants to reduce infection risks also boosts its demand in the pharmaceutical industry.

Its application in decreasing the duration of severe neutropenia after myelosuppressive cancer treatments, as well as in acute myeloid leukaemia recovery, further fuels its demand in the oncology sector. Its usage as an essential tool for mobilising stem cells into the bloodstream for collection via leukapheresis in transplant procedures also contributes to its demand in the modern healthcare sector. Moreover, industrial filgrastim procurement is influenced by factors such as the cost and availability of raw materials, regulatory approvals, and compliance with stringent safety and environmental standards. Technological advancements in bioproduction processes, supplier reliability, quality assurance practices, and efficient logistics also impact its procurement processes.

Raw Material for Filgrastim Production

According to the Filgrastim production plant project report, the major raw materials for Filgrastim production includes Escherichia coli bacteria.

Production Process of Filgrastim

The extensive Filgrastim production cost report consists of the following industrial production process:

1. Production via Recombinant DNA Technology: The production process of filgrastim begins with genetically engineering a plasmid that carries the human G-CSF gene and inserting it into a strain of Escherichia coli bacteria. Then, these transformed bacteria are grown in large fermentation tanks under controlled conditions, where they multiply and produce the Filgrastim peptide as part of their metabolism. After fermentation, the cells are harvested and broken open to release the peptide, which is then purified through a series of steps like filtration, chromatography, and other separation techniques. Finally, these purification steps lead to the formation of the pure, non-glycosylated recombinant protein, filgrastim, as the desired product.

Filgrastim is a recombinant human granulocyte colony-stimulating factor that appears as a sterile, clear, colourless, preservative-free solution for parenteral administration. Its protein chemical formula is C845H1339N223O243S9, and its molecular mass is approximately 18,800 daltons or 18.8 kDa. It is a water-soluble protein consisting of 175 amino acids produced by recombinant DNA technology in Escherichia coli bacteria. The compound is non-glycosylated and has an N-terminal methionine added to its sequence for expression in bacterial hosts. The solution has a pH ranging from 4.0 to 4.1 and must be stored in a refrigerator at 2 degree Celsius to 8 degree Celsius to maintain stability and prevent degradation. The most commonly observed adverse effect is mild to moderate bone pain after repeated administration, and serious allergic reactions have been reported in some patients. It is recommended to visually inspect the solution before use and discard it if particulate matter, discolouration, cloudiness, or foamy appearance is observed.